Immuron shares surge 22.95% intraday as CEO highlights antibody platform at Emerging Growth Conference.

Immuron surged 22.95% intraday following the announcement that its CEO, Steven Lydeamore, will present the company’s antibody platform at the Emerging Growth Conference. The virtual presentation, scheduled for the 22nd, highlights Immuron’s strategic focus on advancing its biopharmaceutical pipeline, which likely generated investor optimism about future growth prospects. The event underscores the firm’s commitment to showcasing its proprietary technology, aligning with the stock’s upward momentum as market participants anticipate potential partnerships or regulatory progress.